<DOC>
	<DOCNO>NCT02172781</DOCNO>
	<brief_summary>Comparative Pharmacokinetics Pharmacodynamics Tiotropium With Ipratropium Placebo After 19 Days Tiotropium Treatment</brief_summary>
	<brief_title>Comparative Pharmacokinetics Pharmacodynamics Tiotropium With Ipratropium Placebo After 19 Days Tiotropium Treatment</brief_title>
	<detailed_description />
	<mesh_term>Ipratropium</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>All participant study healthy male , range 40 65 year age within ±20 % normal weight ( BrocaIndex ) Each subject medical history take receive complete medical examination ( include blood pressure pulse rate measurement ) well 12lead ECG . Haematological , hepatic renal function test carry laboratory ( Bioscentia GmbH , FRG ) . The subject fast 8 hour collection specimens laboratory evaluation . The mentioned examination perform within 14 day first drug administration . In accordance Good Clinical Practice ( GCP ) local legislation subject give write informed consent prior admission study . Following inclusion criterion special interest study : Normal spirometry evidence baseline FEV1 ≥ 80 % predict normal value age , height sex . Predicted normal value calculate accord European Community Coal Steel ( ECCS ) Ability perform technically satisfactory pulmonary function test . Any finding medical examination ( include blood pressure , pulse rate ECG ) deviate normal clinical relevance . Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder . Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder . History orthostatic hypotension , faint spell blackout . Chronic relevant acute infection . History allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator . Intake drug long halflife ( ≥ 24hours ) within least one month less ten halflives respective drug enrolment study study . Use drug might influence result trial seven day prior enrolment study study , among nonselective beta blocker , oral beta adrenergic longacting betaadrenergics salmeterol formoterol , anticholinergic drug include ATROVENT ® ( ipratropium ) oral inhalation ATROVENT® Nasal Spray . Participation another trial investigational drug ( ≤ two month prior administration trial ) . Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke trial day . Alcohol abuse ( &gt; 60g/day ) Drug abuse Blood donation ( ≥ 100 ml within four week prior administration trial ) Any laboratory value outside clinically accept reference range . Excessive physical activity ( within last week study ) Following exclusion criterion special interest study : Subjects know hypersensitivity anticholinergic drug . Subjects know symptomatic prostatic hypertrophy bladder neck obstruction Subjects know narrowangle glaucoma</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>